載入中
NASDAQHealthcareBiotechnology
最新資料
US$24.86
−US$0.06 · -0.24%
SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.
前收盤價
US$24.86
−US$0.06 · -0.24%
盤後
US$24.86
US$0.00 · 0.00%
10月12日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.
日內區間
目前US$24.86
52週區間
目前US$24.86
盤中時間採用ET。市場資料可能有所延遲。
SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.
日內區間
目前US$24.86
52週區間
目前US$24.86
| 項目（USD） | 2025會計年度 |
|---|---|
| 銷貨成本 | 61.2萬 USD |
| 毛利 | −61.2萬 USD |
| 研究與開發 | 2864萬 USD |
| 銷售、一般及管理費用 | 1219.7萬 USD |
| 營業費用 | 4083.7萬 USD |
| 利息收入 | 310.6萬 USD |
| 折舊和攤銷 | 61.2萬 USD |
| 營業利益 | −4144.9萬 USD |
| 淨利 | −3986.9萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI827.51萬0.00%2.3兆 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM615.8萬0.01%787.4億 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF295.59萬0.00%954億 USD0.05%US$233.52-0.63%
Vanguard Russell 2000 ETFVTWO166.09萬0.01%180億 USD0.06%US$112.27-0.35%
iShares Russell 2000 Growth ETFIWO147.46萬0.01%139.17億 USD0.24%US$353.71-0.86%
ALPS Medical Breakthroughs ETFSBIO105.57萬0.56%1.87億 USD0.50%US$53.85-2.16%
Avantis Emerging Markets Equity ETFAVEM104.51萬—281.39億 USD0.33%US$93.27-0.89%
Schwab U.S. Small-Cap ETFSCHA87.81萬0.00%217.13億 USD0.03%US$32.66-0.40%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOALPS Medical Breakthroughs ETFSBIOAvantis Emerging Markets Equity ETFAVEMSchwab U.S. Small-Cap ETFSCHAAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
